ANA test market seen reaching $3.09 billion by 2030

The global antinuclear antibody test market is projected to grow from $1.95 billion in 2026 to $3.09 billion by 2030, driven by rising autoimmune disease rates, precision medicine, and new diagnostic technologies. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Antinuclear antibody testing is a core tool for spotting autoimmune disease early and helping doctors monitor conditions such as lupus and rheumatoid arthritis. - Rising autoimmune diagnoses and broader use of precision diagnostics are expanding demand for ANA testing worldwide. - The market's growth points to more use of automated, high-throughput testing in clinical labs.

What happened: - The global antinuclear antibody test market was valued at $1.73 billion in 2025 and is projected to reach $1.95 billion in 2026. - The market is forecast to grow to $3.09 billion by 2030, reflecting a 12.2% CAGR during the forecast period. - The Business Research Company published the outlook on Oct. 30, 2026. - A sample report is available here. - The full report is available here.

The details: - ANA tests detect autoantibodies that mistakenly target the body's own cells. - The test is used to help diagnose autoimmune diseases and support ongoing disease monitoring. - Historical market growth was tied to rising autoimmune disease prevalence, expanding clinical laboratory services, greater physician reliance on serological tests, wider use of immunofluorescence assays, and higher patient testing volumes. - Forecast growth is linked to artificial intelligence-assisted diagnostic tools, point-of-care autoimmune testing, integrated laboratory information management systems, personalized immune diagnostics, and investment in next-generation assay technologies. - The report highlights growth in multiplex and automated ANA testing, early autoimmune disease screening, digital pathology tied to laboratory information management systems, high-throughput diagnostic platforms, and efforts to improve diagnostic precision and standardization.

Between the lines: - The market shift reflects a broader move from basic lab screening toward more automated and data-driven diagnostics. - Personalized medicine is pushing demand for tests that can better stratify patients and guide treatment decisions. - External data cited in the release points to a larger patient pool, including Arthritis Australia's February 2024 estimate that about 562,378 Australians are projected to live with rheumatoid arthritis by 2025. - The release also cites the Personalized Medicine Coalition's February 2024 report that the U.S. FDA approved 26 new personalized therapies in 2023, including 20 molecular entities and six gene- or cell-based treatments. - North America held the largest market share in 2025, while Asia-Pacific is expected to grow fastest as healthcare access and laboratory capacity expand.

What's next: - Market growth is expected to continue through 2030 as labs adopt more automated platforms and integrated software tools. - The report flags continued investment in next-generation assay technology as a key driver to watch. - Regional expansion in Asia-Pacific could reshape demand as autoimmune awareness and testing capacity improve. - The 2026 edition of the report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, and updated graphics and tables.